Imugene (ASX:IMU) said data from its azer-cel Phase 1b abstract, published on the American Society of Clinical Oncology (ASCO) website, showed an overall response rate (ORR) of 81% among 16 evaluable patients, according to a Friday Australian bourse filing.
The company said Azer-cel, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 to treat blood cancers, showed responses across multiple lymphoma and leukemia subtypes, including a 60% response rate in diffuse large B-cell lymphoma (DLBCL) and a 100% response rate in marginal zone lymphoma (MZL).
The company's shares rose 22% in recent Friday trade.